The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma

R. Dummer, K. Flaherty, R. Kefford, P. A. Ascierto, L. Moutouh-de Parseval, E. Wasserman, D. Schadendorf

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Article number150 (PP17)
Pages (from-to)67-68
Number of pages2
JournalBritish Journal of Dermatology
Issue numberSupplement 4
Publication statusPublished - Sep 2014
Externally publishedYes
Event15th World Congress on Cancers of the Skin - Edinburgh, United Kingdom
Duration: 3 Sep 20146 Sep 2014

Cite this